EUVIMED · CrossrefZeitschrift
Clinical Prostate Cancer
ISSN 1540-0352 · Elsevier BV
Neueste Artikel
Double Primary Cancers of the Prostate and Bladder: A Literature Review
High Androgen Receptor Levels Are Predictive of Decreased Survival in Prostate Cancer
Highlights from the Third Annual Meeting of the Society of Urologic Oncology; Bethesda, Maryland, December 13-14, 2002
Prostate-Specific Antigen Doubling Time Predicts Disease Progression and Survival
Current Studies with Docetaxel in Hormone-Refractory Prostate Cancer: Selected Presentations from the 27th European Society for Medical Oncology Congress, 2002
Highlights from the 98th Annual Meeting of the American Urological Association Chicago, IL April 26 to May 1, 2003
Radical Prostatectomy Improves Cancer-Specific Survival But Not Overall Survival in Early-Stage Prostate Cancer
Androgen-Deprivation Therapy for Prostate Cancer
Models for Prostate Cancer Chemoprevention
Highlights from: The 39th Annual Meeting of the American Society of Clinical Oncology; Chicago, Illinois; May 31–June 3, 2003
Autologous Dendritic Cells Pulsed with Prostatic Acid Phosphatase (APC8015) for Patients with Hormone- Refractory Prostate Cancer with a Gleason Score ≤ 7
Clinical Trials of Atrasentan in Hormone-Refractory Prostate Cancer
Highlights from the XII European Cancer Conference; Copenhagen, Denmark, September 21-25, 2003
The Anti-HER2 Monoclonal Antibody Pertuzumab May Be Effective in Androgen-Independent Prostate Cancer
Ion Channels as Molecular Targets in Prostate Cancer
The Development of Vitamin D–Based Therapies for Prostate Cancer
Finasteride, a Selective 5-Alpha-Reductase Inhibitor, in the Prevention and Treatment of Human Prostate Cancer
Abarelix (Plenaxis™): A Gonadotropin-Releasing Hormone Antagonist for Medical Castration in Patients with Advanced Prostate Cancer
Improved Survival Benefit of Autologous Dendritic Cell–Based Vaccine for Hormone Refractory Prostate Cancer: A Retrospective Subset Analysis of the D9901 Trial
Highlights from the 99th Annual Meeting of the American Urological Association San Francisco, CA May 2004
Docetaxel Improves Survival in Metastatic Androgen-Independent Prostate Cancer
Highlights from the 40th Annual Meeting of the American Society of Clinical Oncology New Orleans, LA June 2004
Benefit of Extended Zoledronate Therapy for Patients with Bone Metastases from Hormone-Refractory Prostate Cancer
Activity of Epothilone B Analogues Ixabepilone and Patupilone in Hormone-Refractory Prostate Cancer
Highlights from the 29th European Society for Medical Oncology Congress Vienna, Austria October 29 through November 2, 2004
Phase I/II Trial of Bortezomib plus Docetaxel in Patients with Advanced Androgen-Independent Prostate Cancer
Role of Magnetic Resonance Spectroscopic Imaging in the Prediction of Treatment Outcome in Prostate Cancer
Highlights from the 2005 American Society of Clinical Oncology prostate Cancer Symposium Orlando, Florida February 17-19, 2005
Role of 5αReductase Inhibitors and Selective Estrogen Receptor Modulators as Potential Chemopreventive Agents for Prostate Cancer
Highlights from the 41st Annual Meeting of the American Society of Clinical Oncology May 2005 and the 2005 American Society of Clinical Oncology Prostate Cancer Symposium February 2005 Orlando, Florida
EUVIMED